Asia Vital Components (3017) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
Revenue for the nine months ended September 30, 2024, was NT$50.86 billion, up 20% year-over-year, with net income of NT$7.58 billion, a 23% increase from the prior year.
Gross margin improved to 23% from 21% year-over-year, and basic EPS rose to NT$15.18 from NT$9.75.
The company maintained strong cash flow, with cash and cash equivalents at NT$30.01 billion as of September 30, 2024.
Segment profit for the nine months was NT$8.69 billion, with both general management and overseas segments contributing significantly.
Financial highlights
Operating income for the nine months reached NT$7.47 billion, up from NT$5.00 billion year-over-year.
Net cash provided by operating activities was NT$8.96 billion, up from NT$6.46 billion in the prior year.
Total assets increased to NT$88.10 billion, up from NT$66.15 billion a year earlier.
Shareholders' equity rose to NT$30.92 billion, compared to NT$22.65 billion at September 30, 2023.
Cash dividends of NT$1.99 per share and capital surplus cash distribution of NT$1.99 per share were approved and distributed.
Outlook and guidance
Management expects continued growth, supported by robust demand in electronic parts and computer peripherals.
No material impact is expected from newly adopted or upcoming accounting standards.
Latest events from Asia Vital Components
- Revenue and net income surged over 80% year-over-year, with robust cash flow and higher EPS.3017
Q3 202519 Dec 2025 - 2024 net income surged over 54% on 21% revenue growth, led by AI server and water-cooling demand.3017
Q4 202430 Nov 2025 - Strong revenue and profit growth, robust liquidity, and solid capital structure for H1 2025.3017
Q2 202525 Aug 2025 - Net income surged 59% year-over-year to NT$3.51B on 19% revenue growth and higher margins.3017
Q2 202413 Jun 2025 - Q1 net income doubled year-over-year on 52% revenue growth and margin expansion.3017
Q1 20256 Jun 2025